BMD at start of study (g/cm2)	BMD at 12 months (g/cm2)	Osteocalcin start of study (ng/ml)	Osteocalcin at 12 months (ng/ml)	Beta-cross laps start of study (mg/ml)	Beta-cross laps at 12 months (mg/ml)
PMA-treated group: N = 41	0.68 ± 0.11	0.73 ± 0.12	24.28 ± 10.9	26.67 ± 8.94	0.39 ± 21	0.34 ± 0.14
Control group, untreated N = 40	0.69 ± 0.12	0.66 ± 0.11	24.82 ± 8.7	23.91 ± 6.89	0.36 ± 0.17	0.39 ± 0.14
		PMA-zeolite-clinoptilolite treated group (N = 41)			Control group (N = 40)	p
Relative Δ BMD, mean ± SD		6.9% ± 5.6%			−4.1% ± 4.1%	<0.001
Relative Δ Osteocalcin, median (IQR)		9.1% (3.4%–23.7%)			0.7% (−13.9%–9.3%)	0.001
Relative Δ Betacross laps, mean ± SD		−0.6% ± 32.6%			21.7% ± 54.3%	0.027